Halozyme Therapeutics Inc.
HALO | NASDAQ
$111.45
-$1 (-0.89%)
At close: Sep 21, 2026, 4:00 PM ET
$112
+$0.55 (+0.49%)
Pre-market:
Sep 22, 2026, 5:27 AM ET
Market Data
Market Cap $13.34B
Enterprise Value $15.14B
Beta 0.88
Average Volume 1.93M
Shares Outstanding (Diluted) 121.22M
Shares Change YoY -2.37%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US40637H1095
Price Performance
Price Change 1M 3.3%
Price Change 3M 60.1%
Price Change 6M 76.2%
Price Change YTD 58.5%
Price Change 1Y 42.4%
Price Change 3Y 181.7%
Price Change 5Y 176.6%
1M CAGR (ann.) 31.1%
1Y CAGR (ann.) 48.3%
5Y CAGR (ann.) 22.2%
All-Time CAGR 20.5%
Valuation
PE Ratio 33.27
Forward PE 10.46
PEG Ratio -1.49
Forward PEG 1.43
PS Ratio 7.95
Forward PS 6.40
PB Ratio 92.09
P/FCF Ratio 16.40
P/Adj. FCF Ratio 17.79
P/OCF Ratio 15.97
EV/Sales 9.10
EV/EBIT 48.33
EV/EBITDA 22.20
EV/FCF 18.77
Earnings Yield 3.0%
FCF Yield 6.1%
Adj. FCF Yield 5.6%
Financial Health
Net Debt $1.92B
Total Debt $2.15B
Cash & Short-Term Investments $231M
Total Assets $2.58B
Current Ratio 2.71
Quick Ratio 2.31
Debt / Equity Ratio 14.95
Debt / EBITDA 3.15
Debt / FCF 2.66
OCF / Debt 0.38
Interest Coverage 46.52
Altman Z-Score 4.69
Piotroski F-Score 5
Margins & Profitability
Gross Profit Margin 78.2%
Operating Profit Margin 56.8%
EBITDA Margin 42.9%
Net Profit Margin 24.9%
FCF Margin 48.5%
Adj. FCF Margin 44.7%
SBC / Revenue 3.8%
SBC Impact (per share) -7.8%
Returns
Return on Assets 16.1%
Return on Equity 180.6%
Return on Invested Capital 27.4%
Return on Capital Employed 42.3%
Return on Tangible Assets 38.5%
Historical Growth (CAGR)
Revenue CAGR 3Y 29.1%
Revenue CAGR 5Y 32.2%
Revenue CAGR 10Y 27.3%
EPS CAGR 3Y 25.1%
EPS CAGR 5Y 16.5%
EPS CAGR 10Y 34.7%
FCF CAGR 3Y 40.2%
FCF CAGR 5Y 40.1%
FCF CAGR 10Y 35.1%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 27
EPS Growth Next 3Y 44.9%
Revenue Growth Next 3Y 8.8%
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number $9.59
Graham Upside -91.4%
Lynch Fair Value $55.34
Lynch Upside -50.4%
Price Target $103
Price Target Upside -7.6%
Cash Flow
Operating Cash Flow $818.6M
Free Cash Flow $806.22M
Adj. Free Cash Flow $743.16M
FCF Per Share $6.87
OCF Per Share $6.98
OCF/S Ratio 49.2%
Income Statement
Revenue $1.66B
Gross Profit $1.3B
Operating Income $944.49M
EBITDA $681.68M
Net Income $413.6M
EPS (Diluted) $3.35
Revenue / Employee $3.93M
Profit / Employee $977.77K
Employees 423
Add to Watchlist
Select watchlists to add or remove HALO